Company Overview
Replimune Group, Inc. operates as a clinical-stage biotechnology entity dedicated to the development and commercialization of oncolytic immunotherapies specifically designed to treat cancer by activating the immune system against malignant cells. This operational focus places the company squarely within the healthcare sector, where it functions specifically within the biotechnology industry, a domain characterized by high-risk research and development aimed at creating novel therapeutic interventions. The company's current scale is defined by a market capitalization of $573.88M, a workforce consisting of 479 employees, and reported net income of $-314,852,992 over the trailing twelve months. These valuation figures indicate that the market values the entity based on its potential future commercialization capabilities rather than current profitability, while the absence of reported revenue suggests the business is still in the pre-revenue or early-stage clinical development phase.
Financial Health
The company reports revenue of N/A, a net income of $-314,852,992, and an EBITDA of $-1,20,000,000, with the gap between these figures highlighting a significant negative operating environment typical of clinical-stage ventures. The free cash flow stands at $-172,752,880, which indicates that the company is currently consuming cash reserves to fund its research and development activities rather than generating liquidity from operations. Analysis of the three reported margins reveals a gross margin of 0.0%, an operating margin of 0.0%, and a profit margin of 0.0%, indicating that the company has not yet achieved profitability from its product sales or operational activities. On the balance sheet, total cash holdings of $269.14M are significantly higher than the total debt of $76.35M, resulting in a debt-to-equity ratio of 36.26, which suggests a capital structure that relies heavily on equity financing while maintaining a low absolute debt burden. The current ratio is reported as 5.60, a figure that indicates a robust short-term liquidity position capable of covering short-term obligations multiple times over. Furthermore, the return on equity is -90.9% and the return on assets is -43.2%, metrics that reveal that management is currently generating negative returns on both shareholder capital and total assets due to the substantial investment required in the clinical pipeline.
Valuation Assessment
The valuation metrics present a trailing P/E ratio of N/A and a forward P/E of -3.46, where the negative forward multiple implies that the market expects the company to remain unprofitable in the near term or that earnings are not yet available for standard valuation comparison. The price-to-book ratio is 2.63, suggesting that the market values the company at a premium of roughly 2.6 times its book value, likely reflecting the intangible value of its proprietary oncolytic immunotherapy product candidates rather than tangible assets. The price-to-sales ratio is N/A and the EV/EBITDA is -1.20, indicating that traditional sales-based or earnings-based valuation multiples are not applicable, and the negative EV/EBITDA reinforces the company's status as a cash-burning entity without established revenue streams. The stock's trading range over the last year spans from a 52-week low of $2.68 to a 52-week high of $13.24, and without a specific current price provided in the facts, the position relative to this range cannot be calculated, though the wide spread indicates significant price volatility typical of small-cap biotech stocks. The beta value is 0.77, which means the stock's price volatility is lower than the broader market, moving with less intensity than the overall market index despite the inherent risks associated with the biotechnology sector.
Growth & Income
The revenue growth year-over-year is N/A and the earnings growth year-over-year is N/A, which precludes any comparison between earnings and revenue growth rates or an analysis of the speed of earnings expansion relative to sales. As the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the company retains all earnings to fund operations and R&D rather than distributing income to shareholders. Consequently, the company reinvests its limited financial resources directly into the development of its oncolytic immunotherapies to advance the clinical pipeline toward commercialization. The overall growth and income profile is characterized by a complete lack of historical revenue growth, negative earnings growth due to net losses, and an absence of dividend income, focusing entirely on capital appreciation potential through future product success.